Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4
inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction
in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact
DPP4 substrates compared to during placebo and compared to matched controls.